FDA Oncology Therapeutics Office Planned; Drug, Biologics Units To Be Merged

The agency is understood to be finalizing a plan that would complete the integration of the oncology review teams as originally intended under the CDER/CBER consolidation. Oncology Drug Products Division Director Richard Pazdur, MD, and ODE VI Director Karen Weiss, MD, are potential candidates to head the merged cancer office.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet